1AD

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens.